Silo Pharma, Inc.

Stage 4 · Declining · week 16

As of Oct 22, 2026, Silo Pharma is in Stage 4, the downtrend phase, now in week 16 (since Jul 2, 2026). It closed at $1.18, 88.2% below its 52-week high and below its 200-day average, which is falling.

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. More about the company

$1.18

-1.67% today

$2.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SILO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S4 16w

S4 17w

S4 24w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 4w → S4 4w → S1 6w → S2 8w → S3 3w → S4 4w → S1 2w → S4 3w → S1 3w → S4 16w → S1 4w → S2 6w → S3 2w → S4 17w → S1 10w → S4 24w → S1 11w → S4 16w current

Total tracked: 165 weeks across 19 stage runs.

SILO among Biotechnology490th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…490	SILOSilo Pharma, Inc.	Stage 4 · wk 16	9	−33.3%

vs 52W High

-88.2%

$1.13 lo$9.99 hi

88.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 16

1w13w26w

Week 16, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-74.9%

200 DMA: $4.70 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.21x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-33.3%

-73.6%

-83.4%

YTD

-76.6%

-86.3%

Scan Membership

Breakout Watch

Latest: 2025-02-18

3 appearances in last 60 days. First seen: 2022-04-11.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 16 · Vol 0.21x

2026-10-21S4

Wk 16 · Vol 0.06x

2026-10-20S4

Wk 16 · Vol 0.08x

2026-10-19S4

Wk 16 · Vol 0.16x

2026-10-16S4

Wk 15 · Vol 0.09x

2026-10-15S4

Wk 15 · Vol 0.12x

2026-10-14S4

Wk 15 · Vol 0.55x

2026-10-13S4

Wk 15 · Vol 1.33x

2026-10-12S4

Wk 15 · Vol 0.19x

2026-10-09S4

Wk 14 · Vol 0.15x

2026-10-08S4

Wk 14 · Vol 0.12x

2026-10-07S4

Wk 14 · Vol 0.19x

Moving averages & range

50 DMA

$1.97

200 DMA

$4.70

52W High

$9.99

52W Low

$1.13

5D Low

$1.13

Resistance levels (recent highs)

20d High

$1.75

60d High

$4.67

120d High

$7.73

250d High

$9.99

Next resistance

+48.3%

to 20d High

ROE

-91.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.3

Silo Pharma: quick answers

What stage is Silo Pharma in?

As of Oct 22, 2026, Silo Pharma (SILO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 2, 2026 and is in week 16. What the four stages mean

Is Silo Pharma in an uptrend?

No. Silo Pharma is in a Stage 4 downtrend. It trades 74.9% below its 200-day average, which is falling.

How far is Silo Pharma from its 52-week high?

Silo Pharma closed at $1.18 on Oct 22, 2026, 88.2% below its 52-week high of $9.99. Its 52-week low is $1.13.

How has Silo Pharma performed over the past year?

As of Oct 22, 2026, Silo Pharma is down 86.3% over the past year and down 76.6% so far in 2026.

Which sector and industry is Silo Pharma in?

Silo Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.